Cargando…

Efficacy and Safety of Combination of NSAIDs and Muscle Relaxants in the Management of Acute Low Back Pain

INTRODUCTION: Low back pain is a common problem worldwide causing deterioration of health and quality of life. Low back pain is often associated with muscle spasm. We investigated the combined effect of muscle relaxants and pain killers for low back pain. METHODS: In this open-label, prospective, mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Himanshu D., Uppin, R. B., Naidu, A. Ramakrishnam, Rao, Y. Ratnakar, Khandarkar, Suhas, Garg, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513919/
https://www.ncbi.nlm.nih.gov/pubmed/30652262
http://dx.doi.org/10.1007/s40122-019-0112-6
_version_ 1783417790608179200
author Patel, Himanshu D.
Uppin, R. B.
Naidu, A. Ramakrishnam
Rao, Y. Ratnakar
Khandarkar, Suhas
Garg, Amit
author_facet Patel, Himanshu D.
Uppin, R. B.
Naidu, A. Ramakrishnam
Rao, Y. Ratnakar
Khandarkar, Suhas
Garg, Amit
author_sort Patel, Himanshu D.
collection PubMed
description INTRODUCTION: Low back pain is a common problem worldwide causing deterioration of health and quality of life. Low back pain is often associated with muscle spasm. We investigated the combined effect of muscle relaxants and pain killers for low back pain. METHODS: In this open-label, prospective, multicenter study, patients with acute low back pain received a single tablet of either the fixed dose combination of chlorzoxazone 500 mg and ibuprofen 400 mg (manufacturer: Dr. Reddy’s Laboratories, India) (C + I group) or ibuprofen 400 mg (I group) thrice daily for up to 7 days. Primary outcomes were improvement in pain by Visual Analogue Scale (VAS) and Summed Pain Intensity Difference (SPID) at 3 and 7 days post-treatment. RESULTS: A total of 406 patients were included in this study. When compared to baseline, the absolute mean change in VAS scores on Day 7 was 62.39 ± 18.78 and 57.34 ± 16.29 in the C + I and I groups, respectively (P = 0.0001). In the C + I and I groups, the mean SPID at Days 3 and 7 were 51.27 ± 24.44 and 47.80 ± 22.91, and 300.82 ± 92.40 and 277.16 ± 81.83, respectively. No deaths or serious adverse events were reported. Common adverse events included gastritis, stomach pain, fever, cold, and headache. At the end of the study, excellent to good response was reported in 94.08% and 77.33% of patients in the C + I and I groups, respectively. Excellent to good tolerability was observed in 96.05% and 89.65% patients in the two groups, respectively. CONCLUSION: Fixed dose combination of chlorzoxazone and ibuprofen demonstrated superior efficacy than ibuprofen monotherapy in acute low back pain. Both drugs were well-tolerated and should be considered as judicious therapeutic options in patients with acute low back pain. TRIAL REGISTRATION: This trial is registered with Clinical Trial Registry of India—CTRI/2016/10/007348. FUNDING: Dr. Reddy’s Laboratories Ltd.
format Online
Article
Text
id pubmed-6513919
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-65139192019-05-28 Efficacy and Safety of Combination of NSAIDs and Muscle Relaxants in the Management of Acute Low Back Pain Patel, Himanshu D. Uppin, R. B. Naidu, A. Ramakrishnam Rao, Y. Ratnakar Khandarkar, Suhas Garg, Amit Pain Ther Original Research INTRODUCTION: Low back pain is a common problem worldwide causing deterioration of health and quality of life. Low back pain is often associated with muscle spasm. We investigated the combined effect of muscle relaxants and pain killers for low back pain. METHODS: In this open-label, prospective, multicenter study, patients with acute low back pain received a single tablet of either the fixed dose combination of chlorzoxazone 500 mg and ibuprofen 400 mg (manufacturer: Dr. Reddy’s Laboratories, India) (C + I group) or ibuprofen 400 mg (I group) thrice daily for up to 7 days. Primary outcomes were improvement in pain by Visual Analogue Scale (VAS) and Summed Pain Intensity Difference (SPID) at 3 and 7 days post-treatment. RESULTS: A total of 406 patients were included in this study. When compared to baseline, the absolute mean change in VAS scores on Day 7 was 62.39 ± 18.78 and 57.34 ± 16.29 in the C + I and I groups, respectively (P = 0.0001). In the C + I and I groups, the mean SPID at Days 3 and 7 were 51.27 ± 24.44 and 47.80 ± 22.91, and 300.82 ± 92.40 and 277.16 ± 81.83, respectively. No deaths or serious adverse events were reported. Common adverse events included gastritis, stomach pain, fever, cold, and headache. At the end of the study, excellent to good response was reported in 94.08% and 77.33% of patients in the C + I and I groups, respectively. Excellent to good tolerability was observed in 96.05% and 89.65% patients in the two groups, respectively. CONCLUSION: Fixed dose combination of chlorzoxazone and ibuprofen demonstrated superior efficacy than ibuprofen monotherapy in acute low back pain. Both drugs were well-tolerated and should be considered as judicious therapeutic options in patients with acute low back pain. TRIAL REGISTRATION: This trial is registered with Clinical Trial Registry of India—CTRI/2016/10/007348. FUNDING: Dr. Reddy’s Laboratories Ltd. Springer Healthcare 2019-01-16 2019-06 /pmc/articles/PMC6513919/ /pubmed/30652262 http://dx.doi.org/10.1007/s40122-019-0112-6 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Patel, Himanshu D.
Uppin, R. B.
Naidu, A. Ramakrishnam
Rao, Y. Ratnakar
Khandarkar, Suhas
Garg, Amit
Efficacy and Safety of Combination of NSAIDs and Muscle Relaxants in the Management of Acute Low Back Pain
title Efficacy and Safety of Combination of NSAIDs and Muscle Relaxants in the Management of Acute Low Back Pain
title_full Efficacy and Safety of Combination of NSAIDs and Muscle Relaxants in the Management of Acute Low Back Pain
title_fullStr Efficacy and Safety of Combination of NSAIDs and Muscle Relaxants in the Management of Acute Low Back Pain
title_full_unstemmed Efficacy and Safety of Combination of NSAIDs and Muscle Relaxants in the Management of Acute Low Back Pain
title_short Efficacy and Safety of Combination of NSAIDs and Muscle Relaxants in the Management of Acute Low Back Pain
title_sort efficacy and safety of combination of nsaids and muscle relaxants in the management of acute low back pain
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513919/
https://www.ncbi.nlm.nih.gov/pubmed/30652262
http://dx.doi.org/10.1007/s40122-019-0112-6
work_keys_str_mv AT patelhimanshud efficacyandsafetyofcombinationofnsaidsandmusclerelaxantsinthemanagementofacutelowbackpain
AT uppinrb efficacyandsafetyofcombinationofnsaidsandmusclerelaxantsinthemanagementofacutelowbackpain
AT naiduaramakrishnam efficacyandsafetyofcombinationofnsaidsandmusclerelaxantsinthemanagementofacutelowbackpain
AT raoyratnakar efficacyandsafetyofcombinationofnsaidsandmusclerelaxantsinthemanagementofacutelowbackpain
AT khandarkarsuhas efficacyandsafetyofcombinationofnsaidsandmusclerelaxantsinthemanagementofacutelowbackpain
AT gargamit efficacyandsafetyofcombinationofnsaidsandmusclerelaxantsinthemanagementofacutelowbackpain